ClinicalTrials.gg
CompletedNCT03292640Updated Mar 1, 2021Results posted

A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks

A Phase 3 interventional study of DFD-03 (0.1% tazarotene) Lotion and DFD-03 (0% tazarotene) Lotion (Placebo) in Acne Vulgaris, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2021-03-01.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
547
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies testing tazarotene in Acne Vulgaris — none open to participants now, none under way, none of them phase 3. tazarotene · Acne Vulgaris.

Enrollment
7th of 17
547 · median 210
Started
2017
with 2 others
Phase 3
5 of 17
none open now
Registered
16th of 17
by date
Lead sponsor
1 of 17
Dr. Reddy's Laboratories Limited

Among the 17 studies testing tazarotene in Acne Vulgaris, this one is the 7th largest by enrollment, is one of 3 that started in 2017, is one of 5 in phase 3, and was the 16th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 17 studies testing tazarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

Where they have run

About tazarotene

tazarotene: first FDA approval 1997 (TAZORAC). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing tazarotene in Acne Vulgaris as a file.
02

Study summary

Enrollment of subjects with mild to moderate facial acne vulgaris.

Co-Primary efficacy endpoints included:

  • Absolute change from Baseline to Week 12 in the inflammatory lesion counts on the face
  • Absolute change from Baseline to Week 12 in the non-inflammatory lesion counts on the face
  • Proportion of subjects with a clinical response of "success" at Week 12 for lesions on the face. Success based on IGA is defined as an IGA score of 0 (Clear) or 1 (Almost clear) at Week 12 with at least a 2-grade reduction from Baseline.
Read the detailed description

Enrollment of subjects with mild to moderate facial acne vulgaris. Acne lesions of any severity on the chest and/or back (including shoulders) were enrolled provided they had mild to moderate acne on the face. During the 12-week treatment period subjects used the study product twice daily with approximately 12 hours between applications. Subjects were instructed to treat the entire face (and chest/back including shoulders, if applicable).

Co-Primary efficacy endpoints included:

  • Absolute change from Baseline to Week 12 in the inflammatory lesion counts on the face
  • Absolute change from Baseline to Week 12 in the non-inflammatory lesion counts on the face
  • Proportion of subjects with a clinical response of "success" at Week 12 for lesions on the face. Success based on IGA is defined as an IGA score of 0 (Clear) or 1 (Almost clear) at Week 12 with at least a 2-grade reduction from Baseline.

The primary safety endpoint was treatment-emergent adverse events (TEAEs). Other safety variables included local cutaneous tolerance evaluation (dryness, non-lesional erythema, peeling, stinging, burning, and itching) and vital signs (blood pressure and pulse rate). Urine pregnancy tests were performed at Baseline and at every visit through Week 12 for all female subjects. A physical examination was performed at the Baseline Visit.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be at least 9 years of age.
  2. Female subjects must be having their period at the Baseline Visit (as reported by the subject), except for subjects using hormonal that preclude menstrual periods, if the subject is premenarcheal, is for at least 12 months prior to baseline, is surgically sterilized (i.e. tubal ligation) or if the subject is without a uterus and /or both ovaries.
  3. A clinical diagnosis of facial mild to moderate acne vulgaris. Subjects with acne lesions on the chest and/or back (including shoulders) in addition to those on the face have the option of treating their back and/or chest (including shoulders) in addition to their face.
  4. Inflammatory lesion count (papules and pustules) of at least 20 on the face, and non-inflammatory lesion count (closed and open comedones) of at least 25 on the face, including the nose, and no more than 2 nodulocystic lesions on the face, including the nose.
  5. Females, regardless of :

    Must have a negative urine pregnancy test and if sexually active, must be on or use an acceptable method of birth control.

  6. Subjects must be willing to comply with sun avoidance measures for the face (as well as back/chest and shoulders, if applicable) including use of investigator-approved sunscreen and/or hats, have limited sun exposure time, and have no tanning bed use.
  7. Subject must be in good general health as determined by the investigator and supported by the medical history, physical examination, and normal or not abnormal vital signs (blood pressure and pulse).

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant or lactating or planning to become pregnant during the study period.
  2. Treatment with the following products:

    1. Topical acne treatments or other topical facial medication on the treatment area in the 14 days prior to the Baseline Visit, including prescription and non-prescription products.
    2. Systemic , systemic acne treatments including systemic antibiotics used for treatment of acne, potential photosensitizing agents spironolactone, flutamide, or drugs in the 30 days prior to the Baseline Visit.
    3. Systemic retinoid use in the 180 days prior to the Baseline Visit.
    4. Undertaken certain facial procedures such as chemical peel, laser treatment, photodynamic therapy, acne surgery, cryodestruction or chemodestruction, x-ray therapy, intralesional steroids, dermabrasion, or depilation (except eyebrow shaping) in the 30 days prior to the Baseline Visit. After the subject is enrolled in the study, eyebrow shaping (except for tweezing) is prohibited.
    5. Treatment with a medication or procedure that, in the opinion of the investigator, would put the subject at unacceptable risk for participation in the study or may interfere with evaluations in the study.
    6. Treatment with an product or device in the 30 days prior to the Baseline Visit.
  3. Known allergic reaction to retinoids or tazarotene or any of the other ingredients of these products.
  4. Presence of any facial skin disease or condition that would interfere with the study or place the subject at unacceptable risk including sunburn, rosacea, seborrheic dermatitis, perioral dermatitis, lupus, dermatomyositis, psoriasis, eczema, squamous cell carcinoma, acneiform eruptions caused by medications, steroid acne, steroid folliculitis, bacterial folliculitis or any other facial disease or condition.
  5. Subjects with a serious and/or chronic medical condition such as chronic or active liver disease, renal impairment, heart disease, severe respiratory disease, rheumatoid arthritis, current , immunocompromised conditions, or any other disease that, in the opinion of the investigator, would interfere with the study or place the subject at unacceptable risk.
  1. Subjects who have been treated for alcohol dependence or alcohol or drug abuse in the year.
  1. Subjects who have been in another investigational trial within 30 days.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
547 participants (actual)

Study arms

  • Experimental
    DFD-03 Lotion (0.1% tazarotene)

    DFD-03 Lotion (0.1% tazarotene)

    Drug: DFD-03 (0.1% tazarotene) Lotion

  • Placebo comparator
    DFD-03 Vehicle (0% tazarotene)

    DFD-03 Vehicle Lotion (0% tazarotene)

    Drug: DFD-03 (0% tazarotene) Lotion (Placebo)

Interventions

  • DFD-03 Lotion (0.1% tazarotene) - twice daily application

    Also known as: DFD-03

  • DrugDFD-03 (0% tazarotene) Lotion (Placebo)

    DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Absolute Change in the Inflammatory Lesion Counts on the Face

    Change in inflammatory lesion counts on the face from baseline to Week 12

    Time frame: Baseline to Week 12

  2. Proportion of Subjects With a Clinical Response of "Success" at Week 12 for Lesions on the Face Based on IGA.

    IGA success at Week 12 (an IGA score of 0 (Clear) or 1 (almost clear) with at least a 2-grade reduction from baseline)

    Time frame: Baseline to Week 12

  3. Absolute Change in the Non-inflammatory Lesion Counts on the Face

    Change in non-inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using the ANCOVA model

    Time frame: Baseline to Week 12

07

Results

Posted Jun 9, 2020

Participant flow

Participant flow — Overall Study
MilestoneDFD-03 Lotion (0.1% Tazarotene)DFD-03 Vehicle (0% Tazarotene)
Started275272
Completed214230
Not completed6142
Withdrew: Withdrawal by subject1716
Withdrew: Adverse event202
Withdrew: Lost to follow-up2424

Outcome measures

PrimaryAbsolute Change in the Inflammatory Lesion Counts on the Face

Change in inflammatory lesion counts on the face from baseline to Week 12

Time frame:
Baseline to Week 12
Reported as:
Mean · Lesions
Absolute Change in the Inflammatory Lesion Counts on the Face
LesionsDFD-03 Lotion (0.1% Tazarotene)DFD-03 Vehicle (0% Tazarotene)
Baseline29.4 ± 13.8229.7 ± 13.27
Week 1215.9 ± 12.1418.2 ± 16.58
PrimaryProportion of Subjects With a Clinical Response of "Success" at Week 12 for Lesions on the Face Based on IGA.

IGA success at Week 12 (an IGA score of 0 (Clear) or 1 (almost clear) with at least a 2-grade reduction from baseline)

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Proportion of Subjects With a Clinical Response of "Success" at Week 12 for Lesions on the Face Based on IGA.
ParticipantsDFD-03 Lotion (0.1% Tazarotene)DFD-03 Vehicle (0% Tazarotene)
Proportion of Subjects With a Clinical Response of "Success" at Week 12 for Lesions on the Face Based on IGA.5826
PrimaryAbsolute Change in the Non-inflammatory Lesion Counts on the Face

Change in non-inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using the ANCOVA model

Time frame:
Baseline to Week 12
Reported as:
Mean · Lesions
Absolute Change in the Non-inflammatory Lesion Counts on the Face
LesionsDFD-03 Lotion (0.1% Tazarotene)DFD-03 Vehicle (0% Tazarotene)
Baseline44.8 ± 33.9344.4 ± 27.75
Week 1224.3 ± 18.1329.7 ± 23.12

Adverse events

Collected over Adverse event data were collected from the time treatment was initiated until study product treatment was discontinued (i.e. up to 12 weeks), except for spontaneously reported SAEs, which were to be reported up to 30 days after discontinuing study product use.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DFD-03 Lotion (0.1% Tazarotene)0/275 (0%)2/275 (0.7%)0/275 (0%)
DFD-03 Vehicle (0% Tazarotene)0/272 (0%)0/272 (0%)0/272 (0%)
Most frequent serious events
Most frequent serious events
EventDFD-03 Lotion (0.1% Tazarotene)DFD-03 Vehicle (0% Tazarotene)
Auto Accident with head traumaInjury, poisoning and procedural complications1/2750/272
Stomach UlcerGastrointestinal disorders1/2750/272

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DFD-03 Lotion (0.1% Tazarotene)DFD-03 Vehicle (0% Tazarotene)Total
<=18 years9385178
Between 18 and 65 years182187369
>=65 years000
Age, Continuous
Age, Continuous(years)DFD-03 Lotion (0.1% Tazarotene)DFD-03 Vehicle (0% Tazarotene)Total
Mean20.7 ± 6.521.3 ± 7.621.0 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)DFD-03 Lotion (0.1% Tazarotene)DFD-03 Vehicle (0% Tazarotene)Total
Female143111254
Male132161293
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DFD-03 Lotion (0.1% Tazarotene)DFD-03 Vehicle (0% Tazarotene)Total
American Indian or Alaska Native112
Asian283260
Native Hawaiian or Other Pacific Islander314
Black or African American454085
White186186372
More than one race000
Unknown or Not Reported121224
Region of Enrollment
Region of Enrollment(participants)DFD-03 Lotion (0.1% Tazarotene)DFD-03 Vehicle (0% Tazarotene)Total
United States275272547
08

Study locations

1 site
  • Center for Dermatology Clinical Research Inc.
    Fremont, California 94538, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in May 2018, 10 months.

Results were first posted in Jun 2020, 2 years after primary completion. A results delay was requested in Sep 2019.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 10 months is below that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2017
First posted
Sep 25, 2017
StartActual
Jul 6, 2017
Primary completionActual
May 14, 2018
CompletionActual
May 14, 2018
Results delay requested
Sep 24, 2019
Results first posted
Jun 9, 2020
Last update
Mar 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03292640
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Jul 6, 2017
Primary completion
May 14, 2018
Completion
May 14, 2018
Results posted
Jun 9, 2020
Last update
Mar 1, 2021

Study contacts

Srinivas R. Sidgiddi, M.D.
study director · Dr. Reddy's Laboratories

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tazarotene

Start the discussion